Submissions
RDNZ actively engages with rare disease issues by responding to calls for submissions.
RDNZ submission on draft statement on disclosure of harm following an adverse event
Rare Disorders NZ made a submission calling for misdiagnosis and delayed diagnosis to be recognised as causing harm.
Submission to Pharmac on proposal to change the access criteria for COVID-19 antiviral treatments
Rare Disorders NZ has been advocating for the widening of access to COVID-19 antiviral treatment for some time and has made a submission to Pharmac on the proposal to change the access criteria.
Submission to Pharmac on Proposal to fund Emicizumab for severe Haemophillia A
Rare Disorders NZ supports the proposal to widen access to emicizumab, brand name Hemlibra, for the treatment of severe Haemophilia A without FVIII inhibitors, subject to eligibility criteria.
Submission to Pharmac on Proposal to fund Ocrelizumab for Primary Progressive Multiple Sclerosis
Rare Disorders NZ supports the changes proposed to the Special Authority Criteria to include access for people with PPMS for Ocrelizumab specifically.
Submission to Pharmac’s review proposal to phase out funding of food thickeners
Rare Disorders NZ proposes that Pharmac does not phase out food thickeners but widen access to include other causes of dysphagia and rare disorders such as Head and Neck cancer.
Submission to Pae Ora Health of Disabled People Strategy
For most rare disorder patients, they experience forms of disability as a result of their condition. Unfortunately, the existing disability support system has proven unable to consistently meet the needs of the rare disorder community in New Zealand.
Submission to the Pae Ora Women’s Health Strategy
Rare disorders affect women, in fact possibly more so than other groups of the population, especially due to women often taking the main carer role.
Submission on the Therapeutic Products Bill
RDNZ is concerned about the risk-proportionate approval systems to ensure New Zealanders especially those living with a rare disorder can access necessary life-saving medicines.
Submission on Proposal to fund Risdiplam (Evrysdi) for Spinal Muscular Atrophy
Rare Disorders NZ fully support the consultation and funding of this drug/medicine as outlined in the consultation proposal.
RDNZ's Submission on rule 8.1b
Rare Disorders NZ supports the expansion of rule 8.1b to include all children with serious illnesses, including those with rare disorders and other life-threatening illnesses where there is a medicine available – currently funded or not.